Sarepta Therapeutics Stock Falls as Some Trials Halted After Patient Death
Some studies of Sarepta Therapeutics' muscular dystrophy drug, Elevidys, have been halted by European regulators after a ...
Sarepta Therapeutics Provides Update on ELEVIDYS
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, shared the following ...
Ousted Vaccine Chief Says RFK Jr.’s Team Sought Data to Justify Anti-Science Stance
Peter Marks says the new health secretary’s team wants to show vaccines aren’t safe while promoting dangerous and unproven ...
Sarepta falls after clinical hold related to Elevidys trials
Shares of Sarepta Therapeutics (NASDAQ:SRPT) fell in the premarket on Thursday following news regarding a clinical hold ...
Biotech Stocks Tumble on Reports FDA's Top Vaccine Regulator to Leave
As director of the FDA's Center for Biologics Evaluation and Research, Marks has publicly supported programs that expedited ...
Sarepta Therapeutics (SRPT) Gets a Hold from RBC Capital
RBC Capital analyst Brian Abrahams maintained a Hold rating on Sarepta Therapeutics (SRPT – Research Report) on April 3 and set a price target ...
Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Upgraded by HC Wainwright
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was upgraded by investment analysts at HC Wainwright from a “sell” ...
Smart Money Is Betting Big In SRPT Options
With a volume of 1,234,594, the price of SRPT is down -6.84% at $58.2. RSI indicators hint that the underlying stock may be ...
Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved ...
Sarepta, Roche seek to resume Elevidys trials
Sarepta (SRPT) and Roche (RHHBY) expect to submit data to address a clinical hold imposed on Elevidys, a gene therapy for ...
TD Cowen Reaffirms Their Buy Rating on Sarepta Therapeutics (SRPT)
In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), with a price ...
Sarepta halts three studies testing gene therapy for muscle disorder
Sarepta Therapeutics said on Friday it had temporarily halted three trials testing its gene therapy Elevidys, following the death of a patient last month upon receiving the treatment.